Earlier studies extensively reported that DLBCL relies on constitutive PI3K signaling to block apoptosis [6-8], indicating the important and translational significance of PI3K/AKT pathway in the clinical therapeutic intervention of DLBCL [9]. Here, AKT1 is linked to diffuse large B-cell lymphoma.